Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2008

Open Access 01-10-2008 | Research article

Recurrence dynamics does not depend on the recurrence site

Authors: Romano Demicheli, Elia Biganzoli, Patrizia Boracchi, Marco Greco, Michael W Retsky

Published in: Breast Cancer Research | Issue 5/2008

Login to get access

Abstract

Introduction

The dynamics of breast cancer recurrence and death, indicating a bimodal hazard rate pattern, has been confirmed in various databases. A few explanations have been suggested to help interpret this finding, assuming that each peak is generated by clustering of similar recurrences and different peaks result from distinct categories of recurrence.

Methods

The recurrence dynamics was analysed in a series of 1526 patients undergoing conservative surgery at the National Cancer Institute of Milan, Italy, for whom the site of first recurrence was recorded. The study was focused on the first clinically relevant event occurring during the follow up (ie, local recurrence, distant metastasis, contralateral breast cancer, second primary tumour), the dynamics of which was studied by estimating the specific hazard rate.

Results

The hazard rate for any recurrence (including both local and distant disease relapses) displayed a bimodal pattern with a first surge peaking at about 24 months and a second peak at almost 60 months. The same pattern was observed when the whole recurrence risk was split into the risk of local recurrence and the risk of distant metastasis. However, the hazard rate curves for both contralateral breast tumours and second primary tumours revealed a uniform course at an almost constant level. When patients with distant metastases were grouped by site of recurrence (soft tissue, bone, lung or liver or central nervous system), the corresponding hazard rate curves displayed the typical bimodal pattern with a first peak at about 24 months and a later peak at about 60 months.

Conclusions

The bimodal dynamics for early stage breast cancer recurrence is again confirmed, providing support to the proposed tumour-dormancy-based model. The recurrence dynamics does not depend on the site of metastasis indicating that the timing of recurrences is generated by factors influencing the metastatic development regardless of the seeded organ. This finding supports the view that the disease course after surgical removal of the primary tumour follows a common pathway with well-defined steps and that the recurrence risk pattern results from inherent features of the metastasis development process, which are apparently attributable to tumour cells.
Appendix
Available only for authorised users
Literature
1.
Demicheli R, Valagussa P, Foroni R, Bonadonna G: Mean relapse rate per year (MRR/Y) suggests different biological conditions of breast cancer micrometastases at the time of primary local-regional treatment. Proc Am Soc Clin Oncol. 1993, 12: 119-
2.
Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G: Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumour dormancy. Breast Cancer Res. Treat. 1996, 41: 177-185. 10.1007/BF01807163.CrossRefPubMed
3.
Demicheli R, Bonadonna G, Hrushesky WJM, Retsky MW, Valagussa P: Menopausal status dependence of the timing of breast cancer recurrence following primary tumour surgical removal. Breast Cancer Res. 2004, 6: R689-696. 10.1186/bcr937.CrossRefPubMedPubMedCentral
4.
Baum M, Badwe RA: Does surgery influence the natural history of breast cancer?. Breast Cancer: Controversies in Management. Edited by: Johnson H Jr. 1994, Armonk, NY: Futura Publishing Company Inc, 61-69.
5.
Fortin A, Larochelle M, Laverdiere J, Lavertu S, Tremblay D: Local failure is responsible for the decrease in survival for patients with breast cancer treated with conservative surgery and postoperative radiotherapy. J Clin Oncol. 1999, 17: 101-109.PubMed
6.
Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M, Boracchi P: Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy. Breast Cancer Res Treat. 2001, 65: 71-75. 10.1023/A:1006476401801.CrossRefPubMed
7.
Jatoi I, Tsimelzon A, Weiss H, Clark GM, Hilsenbeck SG: Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005, 89: 173-178. 10.1007/s10549-004-1722-0.CrossRefPubMed
8.
Demicheli R, Miceli R, Moliterni A, Zambetti M, Hrushesky WJ, Retsky MW, Valagussa P, Bonadonna G: Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumour dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005, 16: 1449-1457. 10.1093/annonc/mdi280.CrossRefPubMed
9.
Jerez JM, Franci L, Alba E, Llombart-Cussiac A, Lluch A, Ribelles N, Munarriz B, Martin M: Improvements of breast cancer prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat. 2005, 94: 265-272. 10.1007/s10549-005-9013-y.CrossRefPubMed
10.
Sant M, Gatta G, Micheli A, Verdecchia A, Capocaccia R, Crosignani P, Berrino F: Survival and age at diagnosis of breast cancer in a population-based cancer registry. Eur J Cancer. 1991, 27: 981-984.CrossRefPubMed
11.
Karrison TG, Ferguson DJ, Meier P: Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999, 91: 80-85. 10.1093/jnci/91.1.80.CrossRefPubMed
12.
Yakovlev AY, Tsodikov AD, Boucher K, Kerber R: The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer. 1999, 85: 1789-1798. 10.1002/(SICI)1097-0142(19990415)85:8<1789::AID-CNCR20>3.0.CO;2-Q.CrossRefPubMed
13.
Gao F, Tan SB, Machin D, Wong NS: Confirmation of double-peaked time distribution of mortality among Asian breast cancer patients in a population-based study. Breast Cancer Res. 2007, 9: R21-10.1186/bcr1658.CrossRefPubMedPubMedCentral
14.
Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G: Proposal for a new model of breast cancer metastatic development. Ann Oncol. 1997, 8: 1075-1080. 10.1023/A:1008263116022.CrossRefPubMed
15.
Retsky MW, Demicheli R, Swartzendruber DE, Bame PD, Wardwell RH, Bonadonna G, Speer JF, Valagussa P: Computer simulation of a breast cancer metastasis model. Breast Cancer Res Treat. 1997, 45: 193-202. 10.1023/A:1005849301420.CrossRefPubMed
16.
Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M, Gallus G, Greco M, Luini A, Marubini E, Muscolino G, Rilke F, Salvadori B, Zecchini A, Zucali R: Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981, 305: 6-11.CrossRefPubMed
17.
Kamby C, Rose C, Ejlertsen B, Andersen J, Birkler NE, Rytter L, Andersen KW, Zedeler K: Stage and pattern of metastases in patients with breast cancer. Eur J Cancer Clin Oncol. 1987, 23: 1925-1934. 10.1016/0277-5379(87)90061-7.CrossRefPubMed
18.
Ramlau-Hansen H: Smoothing counting process intensities by means of Kernel functions. Ann Statistics. 1983, 11: 453-466. 10.1214/aos/1176346152.CrossRef
19.
Boracchi P, Biganzoli E, Marubini E: Joint modelling of cause specific hazard functions with cubic splines: an application to a large series of breast cancer patients. Comput Statist Data Anal. 2003, 42: 243-262. 10.1016/S0167-9473(02)00122-6.CrossRef
20.
Gray RJ: Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis. J Amer Statist Assoc. 1992, 87: 942-951. 10.2307/2290630.CrossRef
21.
Dawson PJ, Maloney T, Gimotty P, Juneau P, Ownby H, Wolman SR: Bilateral breast cancer: one disease or two?. Breast Cancer Res Treat. 1991, 19: 233-244. 10.1007/BF01961160.CrossRefPubMed
22.
Broet P, de la Rochefordiere a, Scholl SM, Fourquet A, Mosseri M, Durand JC, Pouillart P, Asselain B: Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol. 1995, 13: 1578-1583.PubMed
23.
Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond C, Fisher E, Wolmark N, Deutsch M, Montague E, Saffer E, Wickerham L, Lerner H, Glass A, Shibata H, Deckers P, Ketcham A, Oishi R, Russel I: Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med. 1985, 312: 665-673.CrossRefPubMed
24.
Recht A, Silen W, Connolly J, Gelman RS, Rose MA, Silver B, Harris JR: Time-course of local recurrence following conservative surgery and radiotherapy for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1988, 15: 255-261. 10.1016/S0360-3016(98)90002-5.CrossRefPubMed
25.
Hafty BG, Fisher D, Beinfield M, McKhann C: Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991, 21: 293-298.CrossRef
26.
Huang E, Buchholz TA, Meric F, Krishnamurthy S, Mirza NQ, Ames FC, Feig BW, Kuerer HM, Ross MI, Singletary SE, McNeese MD, Strom EA, Hunt KK: Classifying local disease recurrences after breast conservation therapy based on location and histology. New primary tumours have more favourable outcomes than true local disease recurrences. Cancer. 2002, 95: 2059-2067. 10.1002/cncr.10952.CrossRefPubMed
27.
Komoike Y, Akiyama F, Iino Y, Ikeda T, Tanaka-Akashi S, Ohsumi S, Kusama M, Sano M, Shin E, Suemasu K, Sonoo H, Taguchi T, Nishi T, Nishimura R, Haga S, Mise K, Kinoshita T, Murakami S, Yoshimoto M, Tsukuma H, Inaji H: Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors. Breast Cancer. 2005, 12: 104-111. 10.2325/jbcs.12.104.CrossRefPubMed
28.
Smith TE, Lee D, Turner BC, Carter D, Haffty BG: True recurrence vs. new primary ipsilateral breast tumour relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000, 48: 1281-1289.CrossRefPubMed
29.
Voogd AC, van Oost FJ, Rutgers EJT, Elkhuizen PHM, van Geel AN, Scheijmans LJEE, Sangen van der MJC, Botke G, Hoekstra CJ, Jobsen JJ, Velde van de CJH, von Meyenfeldt MF, Tabak JM, Peterse JL, Vijver van de MJ, Coeberg JWW, van Tienhoven G, for the Dutch Study Group on Local Recurrence after Breast Conservation (BORST Group): Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer. 2005, 41: 2637-2644. 10.1016/j.ejca.2005.04.040.CrossRefPubMed
30.
Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biologic properties of disseminating tumour cells. Nat Rev Cancer. 2008, 8: 329-340. 10.1038/nrc2375.CrossRefPubMed
31.
Husemann Y, Geigl JB, Shubert F, Musiani P, Meyer M, Burghert E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA: Systemic spread is an early step in breast cancer. Cancer Cell. 2008, 13: 58-68. 10.1016/j.ccr.2007.12.003.CrossRefPubMed
Metadata
Title
Recurrence dynamics does not depend on the recurrence site
Authors
Romano Demicheli
Elia Biganzoli
Patrizia Boracchi
Marco Greco
Michael W Retsky
Publication date
01-10-2008
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2008
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2152

Other articles of this Issue 5/2008

Breast Cancer Research 5/2008 Go to the issue

Research article

Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1

Research article

Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study

Research article

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study

Research article

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

Editorial

A gene signature of loss of oestrogen receptor (ER) function and oxidative stress links ER-positive breast tumours with an absent progesterone receptor and a poor prognosis

Editorial

The evolving role of oestrogen receptor β in clinical breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits